Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19

Reuters2021-07-06

July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Philipoo
2021-07-07
Philipoo
Well noted
Uta
2021-07-06
Uta
Good
shiauwei
2021-07-06
shiauwei
Good
WonderVeekay
2021-07-06
WonderVeekay
Good
Silverlitz
2021-07-06
Silverlitz
Pls come up vaccine effective against the new variants
NekoCatBin
2021-07-06
NekoCatBin
Pls

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2148801599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-07-06 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2148801599","market":"us","top_or_hot":-1,"title":"Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19","media":"Reuters","content":"<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen says Indian partner's vaccine 93.4% effective against severe COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen says Indian partner's vaccine 93.4% effective against severe COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n2021-07-06 21:05 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":null,"article_id":"2148801599","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2148801599","pubTimestamp":1625576711,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, ha","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"Ocugen说印度合作伙伴的疫苗对严重的新冠肺炎病毒有93.4%的效果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"July 2 (Reuters) - The COVID-19 vaccine developed by Ocugen Inc's Indian partner, Bharat Biotech, has been found to be 93.4% effective against severe cases of COVID-19 in a late-stage trial, the U.S. drug developer said on Friday.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":157482225,"gmtCreate":1625610390167,"gmtModify":1703744708303,"author":{"id":"4087525706477120","authorId":"4087525706477120","name":"Philipoo","avatar":"https://static.tigerbbs.com/6e8a19c2e2e38459c077e596babeb0d6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087525706477120","idStr":"4087525706477120"},"htmlText":"Well noted","listText":"Well noted","text":"Well noted","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157482225","repostId":2148801599,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157230063,"gmtCreate":1625582637052,"gmtModify":1703744392841,"author":{"id":"3586953690582961","authorId":"3586953690582961","name":"Uta","avatar":"https://static.tigerbbs.com/27eb5848beedf4bcbba5726bb52328cf","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3586953690582961","idStr":"3586953690582961"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157230063","repostId":2148801599,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157661686,"gmtCreate":1625580625745,"gmtModify":1703744298310,"author":{"id":"4087635825143120","authorId":"4087635825143120","name":"shiauwei","avatar":"https://static.tigerbbs.com/24735bd6c8d02ebf9b8029d160fc3926","vip":1,"crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"4087635825143120","idStr":"4087635825143120"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157661686","repostId":2148801599,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157840123,"gmtCreate":1625578882462,"gmtModify":1703744193180,"author":{"id":"3574169216532051","authorId":"3574169216532051","name":"WonderVeekay","avatar":"https://static.tigerbbs.com/2b3d611fd7fa30cf140acaba4474e19d","vip":1,"crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3574169216532051","idStr":"3574169216532051"},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157840123","repostId":2148801599,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157859287,"gmtCreate":1625578688449,"gmtModify":1703744180564,"author":{"id":"3570362135363824","authorId":"3570362135363824","name":"Silverlitz","avatar":"https://static.tigerbbs.com/abc7af211be1f2d501fd1885af02f33e","vip":1,"crmLevel":6,"crmLevelSwitch":0,"authorIdStr":"3570362135363824","idStr":"3570362135363824"},"htmlText":"Pls come up vaccine effective against the new variants&nbsp;","listText":"Pls come up vaccine effective against the new variants&nbsp;","text":"Pls come up vaccine effective against the new variants","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157859287","repostId":2148801599,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":157828093,"gmtCreate":1625578536412,"gmtModify":1703744171203,"author":{"id":"3574902235266465","authorId":"3574902235266465","name":"NekoCatBin","avatar":"https://static.tigerbbs.com/fc243854847e0bb4cc112b417d854611","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3574902235266465","idStr":"3574902235266465"},"htmlText":"Pls","listText":"Pls","text":"Pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/157828093","repostId":2148801599,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":84,"commentSize":30,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2148801599"}